新辅助剂在可切除的中国晚期黑色素瘤患者中优于辅助剂方案:淋巴结的保存作为一个关键的免疫优势
Shuguang Hou1,2, Bolun Zhao3, Babo Zhang1
1Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Frontiers in immunology
|October 17, 2025
概括
对于晚期黑色素瘤患者,新辅助疗法与辅助疗法相比,显著改善了无复发生存率 (RFS). 这种方法在状黑色素瘤免疫疗法时代显示出有希望的结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 手术瘤学手术瘤学
背景情况:
- 区域淋巴切除术是黑色素瘤中阳性SLNB的标准,旨在防止转移.
- 最近的研究强调了淋巴结在抗瘤免疫中的作用,质疑剖析的益处,特别是免疫疗法.
- 在东亚人中普遍存在的Acral黑色素瘤,对免疫检查点抑制剂 (ICI) 的反应较差.
研究的目的:
- 评估不同治疗方案在晚期黑色素瘤患者的疗效.
- 将新辅助疗法与辅助疗法,免疫疗法和观察进行比较.
- 评估可切除晚期黑色素瘤的中国患者的无复发生存期 (RFS).
主要方法:
- 对172名患有III-IV期M1a黑色素瘤的患者进行了回顾性分析.
- 患者分为免疫疗法,观察,新辅助和辅助组.
- 免疫疗法涉及使用干扰素-α1b的抗PD-1抗体.
主要成果:
- 新辅助疗法显示RFS明显长于辅助疗法 (HR2.02,p=0.035).
- 新辅助剂的两年RFS率为39.5%,辅助剂为13.8%.
- 两组之间与手术相关的不良事件没有显著差异.
结论:
- 与辅助疗法相比,新辅助疗法在中国晚期黑色素瘤患者中显著延长了RFS.
- 新辅助疗法在其他方法上提供了有意义的,尽管在统计学上并不显著的优势.
- 需要进一步的研究来优化状黑色素瘤的治疗策略,特别是针对ICI的反应.
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K